Press release
Psoriasis Biosimilars Market Future Trends and Scope Analysis Report
According to the latest research by InsightAce Analytic, the Psoriasis Biosimilars Market is valued at US$ 8.5 billion in 2023, and it is expected to reach US$ 19.3 billion by 2031, with a CAGR of 10.9% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2891
A biosimilar is a biologic medication that demonstrates a high degree of similarity to an FDA-approved reference product used in the treatment of psoriasis, an autoimmune skin disorder characterized by accelerated skin cell turnover, inflammation, and scaling. Biosimilars are developed following the expiration of the reference biologic's patent and must adhere to stringent regulatory standards for efficacy, safety, and quality.
The expansion of the psoriasis biosimilars market is primarily driven by the rising global prevalence of psoriasis and the increasing demand for cost-effective treatment alternatives. Additionally, growing awareness among patients and healthcare providers regarding the effectiveness and reliability of biosimilars is fostering greater acceptance and adoption of these treatments.
List of Prominent Players in the Psoriasis Biosimilars Market:
• Merck KGaA
• Coherus BioSciences
• Gyros Protein Technologies AB
• Fresenius Kabi
• Viatris
• Amgen Inc
• Samsung Bioepis Co., Ltd.
• Hoffmann-La Roche Ltd
• Celltrion
• Pfizer Inc.
• Samsung Bioepis
• Sandoz
• Novartis International AG
• Reddy's Laboratories
• GenScript
Market Dynamics:
Drivers-
The rising cost of healthcare has led to an increasing demand for cost-effective treatment alternatives, positioning biosimilars as a viable substitute for traditional biologics. These alternatives offer equivalent therapeutic benefits at a reduced cost, making them particularly advantageous for psoriasis patients by effectively alleviating symptoms and enhancing quality of life. The growing interest from healthcare providers and payers seeking affordable treatment solutions is further propelling market growth. Additionally, government initiatives aimed at supporting biosimilars-particularly in regions with a high prevalence of psoriasis-are accelerating market penetration.
Curious About This Latest Version Of The Report? Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/2891
Challenges:
A significant challenge in the psoriasis biosimilars market is the regulatory uncertainty surrounding their development, approval, and commercialization. The market faces hurdles such as inconsistent regulatory guidelines, evolving frameworks, and stringent requirements for demonstrating biosimilarity and interchangeability. These complexities slow down market expansion and limit patient access to affordable treatment options for psoriasis.
Regional Trends:
The North American psoriasis biosimilars market is expected to capture a substantial revenue share, driven by strong pharmaceutical innovation and a well-established biotechnology research and development infrastructure. Meanwhile, the Asia-Pacific region is witnessing notable market growth, attributed to its advancements in biopharmaceutical technology and the widespread adoption of biosimilars. The high prevalence of psoriasis in the region further underscores the growing need for effective therapies, with biosimilars playing a crucial role in the management of chronic conditions.
Recent Developments:
• In July 2023, Coherus introduced YUSIMRYTM, a biosimilar of Humira®, priced at $995 per carton in the United States. YUSIMRY, sanctioned by the United States Food and Drug Administration (FDA) in 2021, is a tumour necrosis factor (TNF) inhibitor indicated for alleviating the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, as well as for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.
Unlock Your GTM Strategy:
https://www.insightaceanalytic.com/customisation/2891
Segmentation of Psoriasis Biosimilars Market-
By Drug Class-
• TNF-alpha inhibitors
o Infliximab
o Etanercept
o Adalimumab
• Other biosimilars
By Route of Administration-
• Subcutaneous
• Intravenous
• Oral
• Topical
By Indication-
• Plaque psoriasis
• Psoriatic arthritis
• Other types
By Distribution Channel-
• Hospital pharmacies
• Retail pharmacy chains
• Online pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
Get more information:
https://www.insightaceanalytic.com/report/psoriasis-biosimilars-market/2891
Contact us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.JPG
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriasis Biosimilars Market Future Trends and Scope Analysis Report here
News-ID: 3939609 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Vascular Access Device Market is on an Upward Growth Curve
Insightace Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Vascular Access Device Market- by Product (Portal Access Needles, Implantable Ports, Sheath Introducer, IV Safety Catheters, Central Venous Catheter, Peripherally Inserted Central Catheter and Catheter Stabilization), End-User (General Anesthesia, Regional Anesthesia, Oncology, Pain Management, Adult Critical Care, Neo Critical Care and Home and Alternate Care), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
Request for…
PD-1 and PD-L1 Inhibitors Market Report- Expansive Coverage on the Profit Source …
"PD-1 and PD-L1 Inhibitors Market" in terms of revenue was estimated to be worth $ 43.54billion in 2023 and is poised to reach $ 115.90 billion by 2031, growing at a CAGR of 12.81% from 2024 to 2031 according to a new report by InsightAce Analytic.
Request for free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1115
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the PD-1 and PD-L1 inhibitors market are:
• Rising awareness
• Growing…
Molecular Diagnostics Point of Care Market Report on the Untapped Growth Opportu …
"Molecular Diagnostics Point of Care Market" in terms of revenue was estimated to be worth $2.95 billion in 2023 and is poised to reach $6.42 billion by 2031, growing at a CAGR of 10.38% from 2024 to 2031 according to a new report by InsightAce Analytic.
Get Free Sample Report @
https://www.insightaceanalytic.com/request-sample/1423
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global Molecular Diagnostics Point of Care market are:
• Rising…
Vertical Farming Market in 2025 Detailed Study Analysis
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Vertical Farming Market- by Products (Lighting, Hydroponic components, Climate Control, and Sensors), Mechanism (Hydroponics, Aeroponics, and Aquaponics), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the global Vertical Farming Market Size is valued at 6.90 Billion in 2024 and is predicted to reach 50.79 Billion by the…
More Releases for Biosimilars
Global Biosimilars Market 2021-2028 | Price Advantage of Biosimilars Over Biolog …
The global Biosimilars market focuses on encompassing major statistical evidence for the Biosimilars industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition, the Biosimilars study also shifts its attention with an in-depth…
Growth of the Biosimilars Market Is Mainly Driven by Increasing Number of Approv …
A biosimilar is a biologic medical product that is similar to another already approved biological medicine, in terms of quality, safety, and efficacy. Biosimilars are a class of therapeutic drugs that provide additional treatment options and help reduce healthcare costs. Thus, there is an increasing demand for biosimilar drugs due to increasing prevalence of autoimmune diseases, key factor driving the growth of the biosimilars market. According to the National Stem…
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure.
According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is…
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased.
According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was…
Global Oral Biologics and Biosimilars Market | Global Oral Biologics and Biosimi …
The oral biologics and biosimilar market contain of sales of oral biologics and biosimilar products and associated services utilized to treat chronic syndromes such as diabetes, arthritis, cancer. Biologics are drugs completed from living cells using exceedingly complex technology while biosimilars are generated to function similarly to biologics but are not matching to biologics. Biosimilars offer energetic properties as any licensed biologic drug. The oral biologics and biosimilar market encompass…
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million…
